- 360 WallStreet
- Posts
- FDA clears novel sleep apnea treatment
*Sponsored by The Economist I Executive Education
Good day, 360 –
Here are our top investing ideas today. And hey, we’ve got a trade secret for you 🤫 - sponsors keep us alive, so please do us a solid and read/click on the Sponsored links – keep being the best prepared trader on the Street!
FOCUS LIST🔎
VVOS - Up over 100% in pre-market after announcing first ever FDA 510(k) clearance for oral device treatment of severe obstructive sleep apnea
ATXI - Up over 50% in pre after reporting 14.5% passive stake from Robert Davidow
RDHL - Up over 30% in pre after short squeeze
SPOTLIGHT💡
*sponsored by The Economist I Executive Education
Harness The Economist's approach to business writing
How do you write persuasively for business? Study the psychology, craft and purpose of writing with experts from The Economist.
The six-week Professional Communication: Business Writing and Storytelling online short course from The Economist is designed to help business professionals attract and address broad audiences across various written formats.
On completion of this course, you’ll walk away with:
Practical writing, editing and data-visualisation skills for creating clear and compelling business communications.
A writer’s toolkit based on The Economist’s editorial approach, helping you to navigate questions of structure, word choice and style.
The ability to source, structure and convey information in a way that is accurate, engaging and ethical.
HOTLIST🔥
VVOS - Up over 100% in pre-market after announcing first ever FDA 510(k) clearance for oral device treatment of severe obstructive sleep apnea
Vivos Therapeutics (VVOS), a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.
This morning, the company announced the “first ever FDA 510(k) clearance for oral device for treatment of severe obstructive sleep apnea”.
According to Finviz, based on yesterday’s close, the stock had a market cap of only $5.27million and a float of only 1 million shares.
The stock traded up over 100% in pre-market after the news.
The $9 area has acted as support so far in the pre-market and will be an important level to watch.
Above that, targets are $9.80, $10.50 and the pre-market high of $10.69. Beyond that, $11.25 and $14.02 come into play with $20 above that.
Below $9, there is potential support at $7.75, $7, $6 and a gap to fill at $4.39.
ATXI - Up over 50% in pre after reporting 14.5% passive stake from Robert Davidow
Avenue Therapeutics (ATXI) a specialty pharmaceutical company that develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States.
In the aftermarket yesterday Robert Davidow reported a 14.5% passive stake in ATXI in a 13G filing.
Robert is a director in the company and the filing was enough to send ATXI up over 50% in the pre-market.
The $0.28 area was resistance in the after-hours and now becomes a potential level of support.
Above it, targets to the upside are $0.32, $0.36 and then the pre-market high at $0.3750. Beyond that $0.45, $0.55, $0.60 and $0.70 come into play.
Below $0.28, there is potential support at $0.2550, $0.24, $0.22, $0.20 and then a gap to fill at $0.1875.
RDHL - Up over 30% in pre after short squeeze
RedHill Biopharma (RDHL) is a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.\
On Monday, the company announced that it had received from the FDA 5 year US Market exclusivity for Talicia with IP protection running to 2034. It was on the Hotlist Monday, and the stock is gapping another 30% in pre-market this morning as shorts appear to have been trapped. This is one to once again have on your radar this morning.
The $2.80 area has acted as support so far in the pre-market and will be an important level to watch.
Above it, targets to the upside are $3.25, $3.50, $3.66 and then the pre-market high at $4.10. Beyond that, $4.50, $5, and $5.50 come into play. Beyond that, things could get wild.
Below $2.80, there is potential support at $2.50, $2.25, $2, $1.70 and $1.18.
MARKET NEWS
💥 More GREAT trading resources:
Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull
DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer
*Sponsored content: We’re a proud affiliate for Economist I Executive Education, meaning if you click a link for a product or service, we may earn a commission at no extra cost to you. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
Join the conversation